NewsRx

Search our medical news database

Acute Myeloid Leukemia

Acute myeloid leukemia outcome not improved after daunorubicin, cytarabine, and thioguanine therapy

Published in Cancer Weekly, April 10th, 2006

Outcome of pediatric acute myeloid leukemia (AML) was not improved after high-dose daunorubicin, cytarabine, and thioguanine (DAT) therapy and the addition of cyclosporine (CsA).

According to recent research published in the journal Blood, "Relapse is a major obstacle in the cure of AML. The Pediatric Oncology Group AML Study 9421 tested 2 different strategies to improve event-free survival (EFS) and overall survival (OS)."

"Patients were randomized to receive standard-dose DAT or high-dose DAT during induction," explained D. Becton and colleagues, Stanford University. "To interfere with P-glycoprotein (P-g p)-dependent drug efflux, the second...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook